Ellen van der Plas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ellen van der Plas has a total of 263 co-authors. Here are the top co-authors by number of shared publications:
- Peg Nopoulos
Department of Psychiatry Carver College of Medicine at the University of Iowa Iowa City Iowa USA
15 shared publications - Timothy R. Koscik
Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, USA
10 shared publications - Amy Lynn Conrad
University of Iowa College of Medicine, Iowa City, IA, USA
6 shared publications - Brian J. Nieman
Mouse Imaging Centre, The Hospital for Sick Children, Toronto, ON M5T 3H7, Canada
6 shared publications Laurie Gutmann
Department of Psychiatry, University of Iowa Hospital and Clinics, Iowa City, IA, United States
6 shared publications- Lyndsay A. Harshman
University of Iowa Health Care, Stead Family Department of Pediatrics, Division of Nephrology, Dialysis and Transplantation, Iowa City, USA
6 shared publications
Latest Publications
- 28 October 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70747
Population‐Based Assessment of Cardiometabolic Late Effects in 5‐Year Survivors of Pediatric Acute Lymphoblastic Leukemia
Introduction: Survival rates for pediatric acute lymphoblastic leukemia (ALL) have improved substantially, shifting attention toward long‐term health. Epidemiologic data on survivors of pediatric ALL from large, population‐based cohorts, particularly in early survivorship, is limited. We addressed this gap by examining the prevalence of diagnosed cardiometabolic conditions among pediatric ALL survivors compared with matched cancer‐free peers during the fifth year after diagnosis. Methods: We conducted a retrospective cohort study using linked data from the Arkansas Central Cancer Registry (2013–2020) and Arkansas All‐Payer Claims Database (2017–2024). Individuals diagnosed with ALL before age 25 years who survived to the fifth year after diagnosis were identified. We matched ALL survivors with three cancer‐free peers by exact matching on sex, race, ethnicity, birth year, Medicaid enrollment history, and county of residence. Cardiometabolic outcomes were identified using claims‐based diagnoses among the ALL survivors and matched controls. We examined differences in cardiometabolic outcomes between ALL survivors and matched controls. Results: ALL survivors ( n = 142; age range 4–30 years) experienced a significantly higher burden of cardiometabolic conditions compared with matched controls ( n = 426; 10.6% vs. 1.2%, p < 0.01). ALL survivors had higher prevalence of hypertension (4.9% vs. 0.9%; p < 0.01) and diabetes mellitus (4.9% vs. 0.2%; p < 0.01). Differences were more pronounced among ALL survivors aged ≥ 14 years, among whom 20.4% (vs. 2.0%; p < 0.01) had at least one cardiometabolic condition. Conclusions: Pediatric ALL survivors experience elevated cardiometabolic risk as early as five years after diagnosis, particularly during adolescence. Early screening and preventive strategies are needed to reduce long‐term cardiometabolic burden among pediatric ALL survivors.
- 28 October 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70747
Population‐Based Assessment of Cardiometabolic Late Effects in 5‐Year Survivors of Pediatric Acute Lymphoblastic Leukemia
Introduction: Survival rates for pediatric acute lymphoblastic leukemia (ALL) have improved substantially, shifting attention toward long‐term health. Epidemiologic data on survivors of pediatric ALL from large, population‐based cohorts, particularly in early survivorship, is limited. We addressed this gap by examining the prevalence of diagnosed cardiometabolic conditions among pediatric ALL survivors compared with matched cancer‐free peers during the fifth year after diagnosis. Methods: We conducted a retrospective cohort study using linked data from the Arkansas Central Cancer Registry (2013–2020) and Arkansas All‐Payer Claims Database (2017–2024). Individuals diagnosed with ALL before age 25 years who survived to the fifth year after diagnosis were identified. We matched ALL survivors with three cancer‐free peers by exact matching on sex, race, ethnicity, birth year, Medicaid enrollment history, and county of residence. Cardiometabolic outcomes were identified using claims‐based diagnoses among the ALL survivors and matched controls. We examined differences in cardiometabolic outcomes between ALL survivors and matched controls. Results: ALL survivors ( n = 142; age range 4–30 years) experienced a significantly higher burden of cardiometabolic conditions compared with matched controls ( n = 426; 10.6% vs. 1.2%, p < 0.01). ALL survivors had higher prevalence of hypertension (4.9% vs. 0.9%; p < 0.01) and diabetes mellitus (4.9% vs. 0.2%; p < 0.01). Differences were more pronounced among ALL survivors aged ≥ 14 years, among whom 20.4% (vs. 2.0%; p < 0.01) had at least one cardiometabolic condition. Conclusions: Pediatric ALL survivors experience elevated cardiometabolic risk as early as five years after diagnosis, particularly during adolescence. Early screening and preventive strategies are needed to reduce long‐term cardiometabolic burden among pediatric ALL survivors.
- Open Access
Associations between prenatal (poly)phenol intake and cognitive outcomes in school-age children
Background: (Poly)phenol intake is associated with improved cognitive function in adults, with emerging evidence suggesting benefits in children. However, the role of prenatal (poly)phenol exposures in cognitive development remains a gap in early-life nutrition research. Objective: This analysis of a longitudinal cohort tested the associations between prenatal (poly)phenol intakes and cognitive outcomes in school-age children at age 5 and 8 years. Methods: Participants included mother-child pairs enrolled in a prospective, longitudinal study during pregnancy and completed 5- and 8-year follow-up visits (N = 129). 3-day food records were used to estimate prenatal and child intakes of energy and 18 (poly)phenol subclasses using a database developed from Phenol-Explorer (v3.6). The analytical sample included children (N = 111) with completed assessments for academic achievement, language skills, and intelligence quotient (IQ) scores (Mean = 100, SD = 15). Regression models estimated associations between (poly)phenol intakes and cognitive outcomes, adjusted for breastfeeding duration, maternal IQ, pre-pregnancy BMI, gestational age, and infant sex. Results: Average prenatal total (poly)phenol intake was 716 ± 383 mg/d. Prenatal (poly)phenol intakes were not associated with child academic achievement scores. Higher prenatal flavone intakes were associated with higher language (β: 4.36, p = 0.045) and IQ (β: 9.43, p = 0.002) scores. Higher flavonol (β: −4.67, p = 0.022) or hydroxybenzoic acid intakes (β: −3.88, p = 0.026) were associated with lower language scores. Major sources of flavones and lignans included coffee, orange juice, and herbal tea. Coffee, cranberry, black tea, okra, and tomato sauce provided flavonols and hydroxybenzoic acids. Conclusions: Associations between prenatal (poly)phenol intake and child cognitive outcomes were mixed and differed by subclass. Further investigation is needed to explore the role of co-occurring nutrients and other dietary components. These findings suggest that (poly)phenol subclasses derived from healthier plant-based foods, including citrus fruit and herbal tea, may associate with improved child cognitive outcomes. Clinical Trial Registry number: NCT01131117, https://clinicaltrials.gov/study/NCT01131117 ; NCT03108001 , https://clinicaltrials.gov/study/NCT03108001
Open AccessAssociations between prenatal (poly)phenol intake and cognitive outcomes in school-age children
Background: (Poly)phenol intake is associated with improved cognitive function in adults, with emerging evidence suggesting benefits in children. However, the role of prenatal (poly)phenol exposures in cognitive development remains a gap in early-life nutrition research. Objective: This analysis of a longitudinal cohort tested the associations between prenatal (poly)phenol intakes and cognitive outcomes in school-age children at age 5 and 8 years. Methods: Participants included mother-child pairs enrolled in a prospective, longitudinal study during pregnancy and completed 5- and 8-year follow-up visits (N = 129). 3-day food records were used to estimate prenatal and child intakes of energy and 18 (poly)phenol subclasses using a database developed from Phenol-Explorer (v3.6). The analytical sample included children (N = 111) with completed assessments for academic achievement, language skills, and intelligence quotient (IQ) scores (Mean = 100, SD = 15). Regression models estimated associations between (poly)phenol intakes and cognitive outcomes, adjusted for breastfeeding duration, maternal IQ, pre-pregnancy BMI, gestational age, and infant sex. Results: Average prenatal total (poly)phenol intake was 716 ± 383 mg/d. Prenatal (poly)phenol intakes were not associated with child academic achievement scores. Higher prenatal flavone intakes were associated with higher language (β: 4.36, p = 0.045) and IQ (β: 9.43, p = 0.002) scores. Higher flavonol (β: −4.67, p = 0.022) or hydroxybenzoic acid intakes (β: −3.88, p = 0.026) were associated with lower language scores. Major sources of flavones and lignans included coffee, orange juice, and herbal tea. Coffee, cranberry, black tea, okra, and tomato sauce provided flavonols and hydroxybenzoic acids. Conclusions: Associations between prenatal (poly)phenol intake and child cognitive outcomes were mixed and differed by subclass. Further investigation is needed to explore the role of co-occurring nutrients and other dietary components. These findings suggest that (poly)phenol subclasses derived from healthier plant-based foods, including citrus fruit and herbal tea, may associate with improved child cognitive outcomes. Clinical Trial Registry number: NCT01131117, https://clinicaltrials.gov/study/NCT01131117 ; NCT03108001 , https://clinicaltrials.gov/study/NCT03108001
- Open Access
Long-Term Brain White Matter Outcomes Following Neonatal Acute Kidney Injury
Acute kidney injury (AKI) is common among neonates in the intensive care unit and has been linked to abnormal neurodevelopment, yet long-term effects on brain structure remain uncharacterized. In this secondary analysis, we compared brain white matter integrity, measured by fractional anisotropy (FA) on 3T MRI, in children ages 5-12 years born preterm with (n=5) versus without (n=10) a history of neonatal AKI. Contrary to our hypothesis, children with prior neonatal AKI showed higher FA across seven white matter regions in unadjusted analyses. After adjustment for sex, birth weight, and age at MRI, the AKI group retained significantly greater FA in the corticospinal tract (β=0.7, 95% CI 0.09-1.31) and superior frontooccipital fasciculus (β=0.68, 95% CI 0.02-1.34). Because elevated FA may reflect compensatory glial responses rather than improved neurological function, these findings suggest neonatal AKI may have lasting, complex effects on white matter microstructure. Larger studies pairing neuroimaging with neurocognitive assessment are needed.
Open AccessLong-Term Brain White Matter Outcomes Following Neonatal Acute Kidney Injury
Acute kidney injury (AKI) is common among neonates in the intensive care unit and has been linked to abnormal neurodevelopment, yet long-term effects on brain structure remain uncharacterized. In this secondary analysis, we compared brain white matter integrity, measured by fractional anisotropy (FA) on 3T MRI, in children ages 5-12 years born preterm with (n=5) versus without (n=10) a history of neonatal AKI. Contrary to our hypothesis, children with prior neonatal AKI showed higher FA across seven white matter regions in unadjusted analyses. After adjustment for sex, birth weight, and age at MRI, the AKI group retained significantly greater FA in the corticospinal tract (β=0.7, 95% CI 0.09-1.31) and superior frontooccipital fasciculus (β=0.68, 95% CI 0.02-1.34). Because elevated FA may reflect compensatory glial responses rather than improved neurological function, these findings suggest neonatal AKI may have lasting, complex effects on white matter microstructure. Larger studies pairing neuroimaging with neurocognitive assessment are needed.
- Open Access
Feasibility of Non-Sedated Multispectral Neuroimaging in Newly Diagnosed Children with Leukemia
Introduction: Children with acute lymphoblastic leukemia (ALL) require neurotoxic treatment during critical periods of brain development. Multispectral magnetic resonance imaging (MRI) offers opportunities to characterize the impact of chemotherapy on the developing brain, but this has been constrained by concerns regarding feasibility of obtaining quality MRIs from these critically ill children at a young age. Our goal is to demonstrate a framework for improving the feasibility of non-sedated, multispectral MRI in newly diagnosed ALL patients. Methods: Participants were enrolled from August 2023 through February 2026, and included newly diagnosed ALL patients and controls recruited from the community ages 3-10 years old. Participants completed a series of three non-sedated MRI without contrast on a 3T scanner over 12 months. Sequences included anatomical T1-weighted and QALAS sequences for quantitative mapping, diffusion weighted MRI (DWI), MR Spectroscopy (MRS), and resting-state functional MRI (rs-fMRI). A sequence was considered complete if data quality was sufficient for successful image processing. Mixed-effects logistic regression models were used determine if group and study visit were associated with MRI success rates across sequences. Results: The sample included 17 ALL patients and 30 controls, who contributed to 38 and 75 observations, respectively. Of 113 attempted scans, 105 had ≥1 sequence completed (93%). Across assessments, ALL patients were less likely to complete a scan (31 of 38 attempts; raw rate: 82%) relative to controls (73 of 75; raw rate: 96%; model-estimated difference=-14.1%, 95%CI=-27.1%; -1.1%, p=0.033). Baseline success rate was 65% (11 of 17) for ALL patients and 93% (28 of 30) for controls (model-estimated difference=-26.8%, 95%CI=-52.7%; -0.9%, p=0.42); however, nearly all T1w scans in ALL patients were successful at follow-up visits (20 of 21; 95%), with no significant differences between groups (model-estimated difference at follow-up 1=-2.1%, 95%CI=-11.7%; 7.6%; model-estimated difference at follow-up 2=-8.3%, 95%CI=-26.3%; 9.6%). A similar pattern was observed for DWI, MRS and rs-fMRI sequences with relatively high completion rates at follow-up assessments. Discussion: Non-sedated multispectral MRI is feasible in young children with newly diagnosed ALL, particularly with repeated visits and structured behavioral preparation. These results highlight opportunities to capture the scope and depth of neurodevelopmental changes concurrent with ALL treatment.
Open AccessFeasibility of Non-Sedated Multispectral Neuroimaging in Newly Diagnosed Children with Leukemia
Introduction: Children with acute lymphoblastic leukemia (ALL) require neurotoxic treatment during critical periods of brain development. Multispectral magnetic resonance imaging (MRI) offers opportunities to characterize the impact of chemotherapy on the developing brain, but this has been constrained by concerns regarding feasibility of obtaining quality MRIs from these critically ill children at a young age. Our goal is to demonstrate a framework for improving the feasibility of non-sedated, multispectral MRI in newly diagnosed ALL patients. Methods: Participants were enrolled from August 2023 through February 2026, and included newly diagnosed ALL patients and controls recruited from the community ages 3-10 years old. Participants completed a series of three non-sedated MRI without contrast on a 3T scanner over 12 months. Sequences included anatomical T1-weighted and QALAS sequences for quantitative mapping, diffusion weighted MRI (DWI), MR Spectroscopy (MRS), and resting-state functional MRI (rs-fMRI). A sequence was considered complete if data quality was sufficient for successful image processing. Mixed-effects logistic regression models were used determine if group and study visit were associated with MRI success rates across sequences. Results: The sample included 17 ALL patients and 30 controls, who contributed to 38 and 75 observations, respectively. Of 113 attempted scans, 105 had ≥1 sequence completed (93%). Across assessments, ALL patients were less likely to complete a scan (31 of 38 attempts; raw rate: 82%) relative to controls (73 of 75; raw rate: 96%; model-estimated difference=-14.1%, 95%CI=-27.1%; -1.1%, p=0.033). Baseline success rate was 65% (11 of 17) for ALL patients and 93% (28 of 30) for controls (model-estimated difference=-26.8%, 95%CI=-52.7%; -0.9%, p=0.42); however, nearly all T1w scans in ALL patients were successful at follow-up visits (20 of 21; 95%), with no significant differences between groups (model-estimated difference at follow-up 1=-2.1%, 95%CI=-11.7%; 7.6%; model-estimated difference at follow-up 2=-8.3%, 95%CI=-26.3%; 9.6%). A similar pattern was observed for DWI, MRS and rs-fMRI sequences with relatively high completion rates at follow-up assessments. Discussion: Non-sedated multispectral MRI is feasible in young children with newly diagnosed ALL, particularly with repeated visits and structured behavioral preparation. These results highlight opportunities to capture the scope and depth of neurodevelopmental changes concurrent with ALL treatment.
- Open Access
- 20 November 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (22) , e71394
Association Between Sensorineural Hearing Loss and Neurocognitive Performance in Survivors of Childhood Cancer: A Systematic Review and Meta‐Analysis
Background: Various studies have shown that sensorineural hearing loss (SNHL) is associated with neurocognitive impairment among childhood cancer survivors, though prior studies are limited by small sample sizes and inconsistent methods. Objective: This systematic review and meta‐analysis aimed to quantify neurocognitive differences between survivors with severe SNHL (s‐SNHL) and those without. Methods: Studies were included if they evaluated childhood cancer survivors (diagnosed ≤ 21 years), were ≥ 2 years posttreatment, received cranial radiation and/or platinum‐based chemotherapy, used validated neurocognitive tests, and included survivors with and without SNHL. Methods and reporting adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Databases searched included PubMed, Web of Science, Cochrane, Scopus, PsycINFO, and Embase. Study quality was assessed using an adapted version of the Newcastle–Ottawa Scale. We collected study details, including authors, year, neurocognitive tests used, sample sizes, and group scores (means and standard deviations [SD]). Pooled mean differences (MD) and 95% confidence intervals (95% CI) were calculated using standard scores (mean = 100, SD = 15) and random‐effects models. Results: Of 1012 records identified, nine studies were included in the analyses, with 503 childhood cancer survivors with s‐SNHL and 1553 survivors without s‐SNHL. Compared to survivors without s‐SNHL, survivors with s‐SNHL scored lower on measures of overall intellectual functioning (MD = −8.1, 95% CI = −10.0, −6.2), verbal reasoning (MD = −9.7, 95% CI = −11.4, −7.9), perceptual reasoning (MD = −6.6, 95% CI = −11.1, −2.1), working memory (MD = −5.3, 95% CI = −7.1, −3.4), processing speed (MD = −6.3, 95% CI = −9.9, −2.6), short‐term visual memory (MD = −6.0, 95% CI = −8.2, −3.7), and reading (MD = −6.2, 95% CI = −7.9, −4.5). Conclusions: Severe SNHL is associated with significant neurocognitive deficits in childhood cancer survivors. Routine hearing screening and timely neurocognitive assessments are recommended to identify and address these impairments. Trial Registration: PROSPERO: CRD42023440952
- 20 November 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (22) , e71394
Open AccessAssociation Between Sensorineural Hearing Loss and Neurocognitive Performance in Survivors of Childhood Cancer: A Systematic Review and Meta‐Analysis
Background: Various studies have shown that sensorineural hearing loss (SNHL) is associated with neurocognitive impairment among childhood cancer survivors, though prior studies are limited by small sample sizes and inconsistent methods. Objective: This systematic review and meta‐analysis aimed to quantify neurocognitive differences between survivors with severe SNHL (s‐SNHL) and those without. Methods: Studies were included if they evaluated childhood cancer survivors (diagnosed ≤ 21 years), were ≥ 2 years posttreatment, received cranial radiation and/or platinum‐based chemotherapy, used validated neurocognitive tests, and included survivors with and without SNHL. Methods and reporting adhered to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Databases searched included PubMed, Web of Science, Cochrane, Scopus, PsycINFO, and Embase. Study quality was assessed using an adapted version of the Newcastle–Ottawa Scale. We collected study details, including authors, year, neurocognitive tests used, sample sizes, and group scores (means and standard deviations [SD]). Pooled mean differences (MD) and 95% confidence intervals (95% CI) were calculated using standard scores (mean = 100, SD = 15) and random‐effects models. Results: Of 1012 records identified, nine studies were included in the analyses, with 503 childhood cancer survivors with s‐SNHL and 1553 survivors without s‐SNHL. Compared to survivors without s‐SNHL, survivors with s‐SNHL scored lower on measures of overall intellectual functioning (MD = −8.1, 95% CI = −10.0, −6.2), verbal reasoning (MD = −9.7, 95% CI = −11.4, −7.9), perceptual reasoning (MD = −6.6, 95% CI = −11.1, −2.1), working memory (MD = −5.3, 95% CI = −7.1, −3.4), processing speed (MD = −6.3, 95% CI = −9.9, −2.6), short‐term visual memory (MD = −6.0, 95% CI = −8.2, −3.7), and reading (MD = −6.2, 95% CI = −7.9, −4.5). Conclusions: Severe SNHL is associated with significant neurocognitive deficits in childhood cancer survivors. Routine hearing screening and timely neurocognitive assessments are recommended to identify and address these impairments. Trial Registration: PROSPERO: CRD42023440952
- Open Access
- 1 July 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (7) , e2519793
Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease
Importance: Adverse childhood experiences (ACEs) are associated with poor health care use. In African American communities, where ACEs are more prevalent, it is critical to understand the association of ACEs with chronic illnesses, such as sickle cell disease (SCD), in children to expand trauma-informed care and improve outcomes.Objective: To examine the association between parental ACEs and health care use in pediatric patients with SCD, accounting for factors that may influence this association.Design, Setting, and Participants: This unblinded cross-sectional study was conducted from January 1, 2020, to December 31, 2023, at Arkansas Children’s Hospital. Seventy-two of 77 approached caregivers (93.5%) participated. All resided within the Arkansas Children’s Hospital catchment area.Exposure: Parental ACEs and resiliency were assessed using the Adverse Childhood Experiences Questionnaire (ACE-Q) and the Brief Resiliency Scale, respectively. Neighborhood deprivation was assessed using the Area Deprivation Index (ADI).Main Outcomes and Measures: Primary outcomes included number of visits to the emergency department (ED), number of missed clinic visits, and medication adherence (categorical outcomes). Independent variables included parental ACEs, parental resilience, and neighborhood ADI. Coefficients were derived from mixed regression models.Results: The final sample included 79 observations (mean [SD] patient age, 9.73 [4.88] years; 44 [55.7%] female) from 72 caregivers (6 reporting for >1 child), with 70 (88.6%) of ACE-Q respondents being mothers. The ACE risk was low in 32 caregivers (40.5%), intermediate in 33 (41.8%), and high in 14 (17.7%). Patients whose caregivers were at high risk had significantly more ED visits and admissions compared with those whose caregivers were at low risk (regression coefficient = 7.35; 95% CI, 1.77-12.94). Likewise, the number of ED visits and admissions was higher among patients whose caregivers had lower resiliency compared with those with more resilient caregivers (regression coefficient = 5.69; 95% CI, 0.13-11.26). ADI was not significantly associated with ED visits and admissions (regression coefficient = −0.02; 95% CI, −0.12 to 0.08). Parental ACEs were not significantly associated with other metrics of health care use.Conclusions and Relevance: This cross-sectional study of ACEs and resiliency in parents of children with SCD found that higher levels of parental ACE scores and lower resiliency were associated with visits to the ED. These findings support the importance of screening caregivers for ACEs and resilience to enhance trauma-informed care, particularly in marginalized populations.
- 1 July 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (7) , e2519793
Open AccessParental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease
Importance: Adverse childhood experiences (ACEs) are associated with poor health care use. In African American communities, where ACEs are more prevalent, it is critical to understand the association of ACEs with chronic illnesses, such as sickle cell disease (SCD), in children to expand trauma-informed care and improve outcomes.Objective: To examine the association between parental ACEs and health care use in pediatric patients with SCD, accounting for factors that may influence this association.Design, Setting, and Participants: This unblinded cross-sectional study was conducted from January 1, 2020, to December 31, 2023, at Arkansas Children’s Hospital. Seventy-two of 77 approached caregivers (93.5%) participated. All resided within the Arkansas Children’s Hospital catchment area.Exposure: Parental ACEs and resiliency were assessed using the Adverse Childhood Experiences Questionnaire (ACE-Q) and the Brief Resiliency Scale, respectively. Neighborhood deprivation was assessed using the Area Deprivation Index (ADI).Main Outcomes and Measures: Primary outcomes included number of visits to the emergency department (ED), number of missed clinic visits, and medication adherence (categorical outcomes). Independent variables included parental ACEs, parental resilience, and neighborhood ADI. Coefficients were derived from mixed regression models.Results: The final sample included 79 observations (mean [SD] patient age, 9.73 [4.88] years; 44 [55.7%] female) from 72 caregivers (6 reporting for >1 child), with 70 (88.6%) of ACE-Q respondents being mothers. The ACE risk was low in 32 caregivers (40.5%), intermediate in 33 (41.8%), and high in 14 (17.7%). Patients whose caregivers were at high risk had significantly more ED visits and admissions compared with those whose caregivers were at low risk (regression coefficient = 7.35; 95% CI, 1.77-12.94). Likewise, the number of ED visits and admissions was higher among patients whose caregivers had lower resiliency compared with those with more resilient caregivers (regression coefficient = 5.69; 95% CI, 0.13-11.26). ADI was not significantly associated with ED visits and admissions (regression coefficient = −0.02; 95% CI, −0.12 to 0.08). Parental ACEs were not significantly associated with other metrics of health care use.Conclusions and Relevance: This cross-sectional study of ACEs and resiliency in parents of children with SCD found that higher levels of parental ACE scores and lower resiliency were associated with visits to the ED. These findings support the importance of screening caregivers for ACEs and resilience to enhance trauma-informed care, particularly in marginalized populations.
- Open Access
An Activation Likelihood Estimation Meta-Analysis of Voxel-Based Morphometry Studies of Chemotherapy-Related Brain Volume Changes in Breast Cancer
Background/Objectives: Breast cancer chemotherapy patients and survivors face cognitive side effects that are not fully understood. Neuroimaging can provide a unique way to study these effects; however, it can be difficult to recruit large numbers of subjects. Our meta-analysis aims to synthesize volumetric neuroimaging data to highlight consistent findings in regional brain volume changes to further advance our understanding of the chemotherapy-related cognitive impairments faced by breast cancer patients and survivors. Methods: An Activation Likelihood Estimation analysis was conducted across the data from eight voxel-based morphometry experiments examining changes in the brains of breast cancer patients and survivors exposed to chemotherapy over time and three voxel-based morphometry experiments comparing chemotherapy-exposed subjects to controls with and without breast cancer. Results: There were consistent volume reductions across the whole brain in both experiment groups. The subjects’ over-time analysis showed peak consistency among the studies in the right inferior frontal gyrus and the left insula. Conclusions: Chemotherapy for non-central nervous system cancers such as breast cancer can cause physical changes throughout the brain that can be quantitatively measured by neuroimaging methodologies and may underlie persistent cognitive deficits in some individuals.
Open AccessAn Activation Likelihood Estimation Meta-Analysis of Voxel-Based Morphometry Studies of Chemotherapy-Related Brain Volume Changes in Breast Cancer
Background/Objectives: Breast cancer chemotherapy patients and survivors face cognitive side effects that are not fully understood. Neuroimaging can provide a unique way to study these effects; however, it can be difficult to recruit large numbers of subjects. Our meta-analysis aims to synthesize volumetric neuroimaging data to highlight consistent findings in regional brain volume changes to further advance our understanding of the chemotherapy-related cognitive impairments faced by breast cancer patients and survivors. Methods: An Activation Likelihood Estimation analysis was conducted across the data from eight voxel-based morphometry experiments examining changes in the brains of breast cancer patients and survivors exposed to chemotherapy over time and three voxel-based morphometry experiments comparing chemotherapy-exposed subjects to controls with and without breast cancer. Results: There were consistent volume reductions across the whole brain in both experiment groups. The subjects’ over-time analysis showed peak consistency among the studies in the right inferior frontal gyrus and the left insula. Conclusions: Chemotherapy for non-central nervous system cancers such as breast cancer can cause physical changes throughout the brain that can be quantitatively measured by neuroimaging methodologies and may underlie persistent cognitive deficits in some individuals.
- Open Access
- 26 July 2024
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 1 (4)
Regional brain volumes and their relationship to neurocognitive outcomes in children with severe hemophilia A
- 26 July 2024
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 1 (4)
Open AccessRegional brain volumes and their relationship to neurocognitive outcomes in children with severe hemophilia A
- Open Access
- 1 March 2024
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 13 (3) , 408-416
Characterization of brain development with neuroimaging in a female mouse model of chemotherapy treatment of acute lymphoblastic leukemia
Background: Survivors of pediatric acute lymphoblastic leukemia (ALL) exhibit abnormal neurocognitive outcomes that are possibly due to exposures to neurotoxic chemotherapy agents. This study aimed to determine the feasibility of characterizing long-term neuroanatomical changes with in vivo neuroimaging in a preclinical model of treatment for ALL. Methods: Female mice (C57BL/6) were randomly assigned to a saline control group (n=10) or a treatment group (n=10) that received intrathecal methotrexate and oral dexamethasone (IT-MTX + DEX). Mice were subsequently scanned three times on a 7T MRI at ages 3, 6, and 12 months (T1, T2, and T3, respectively), which corresponds with human age-equivalents spanning early to late adulthood. Regional brain volumes were automatically segmented, and volume change between timepoints (i.e., T1 to T2; and T2 to T3) were compared between groups (i.e., saline vs. IT-MTX + DEX). Results: Five mice in the IT-MTX + DEX group, and seven mice in the saline group completed all three scans. Between T1 and T2, volumetric change was significantly different between groups in total gray matter [estimate =2.06, 95% confidence interval (CI): 0.27–3.84], the cerebrum (estimate =1.62, 95% CI: 0.14–3.09), claustrum (estimate =0.06, 95% CI: 0.02–0.09), amygdala (estimate =0.16, 95% CI: 0.03–0.29), and striatum (estimate =0.18, 95% CI: 0.01–0.35), with the IT-MTX + DEX group exhibiting a more robust increase in volume than the saline-treated group. Between T2 and T3, group differences in structural brain development were evident for total white matter (estimate =−0.14, 95% CI: −0.27 to −0.01), and the corpus callosum (estimate =−0.09, 95% CI: −0.19 to 0.00) and amygdala (estimate =−0.05, 95% CI: −0.10 to 0.00). In contrast to the rapid brain growth observed earlier in development (i.e., T1 to T2), the IT-MTX + DEX group exhibited an attenuated increase in volume relative to the saline-treated group between T2 and T3. Conclusions: The results demonstrate feasibility of modeling pediatric ALL treatment in a preclinical model and highlight the potential of using preclinical neuroimaging models to gain insight into brain development throughout survivorship.
- 1 March 2024
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 13 (3) , 408-416
Open AccessCharacterization of brain development with neuroimaging in a female mouse model of chemotherapy treatment of acute lymphoblastic leukemia
Background: Survivors of pediatric acute lymphoblastic leukemia (ALL) exhibit abnormal neurocognitive outcomes that are possibly due to exposures to neurotoxic chemotherapy agents. This study aimed to determine the feasibility of characterizing long-term neuroanatomical changes with in vivo neuroimaging in a preclinical model of treatment for ALL. Methods: Female mice (C57BL/6) were randomly assigned to a saline control group (n=10) or a treatment group (n=10) that received intrathecal methotrexate and oral dexamethasone (IT-MTX + DEX). Mice were subsequently scanned three times on a 7T MRI at ages 3, 6, and 12 months (T1, T2, and T3, respectively), which corresponds with human age-equivalents spanning early to late adulthood. Regional brain volumes were automatically segmented, and volume change between timepoints (i.e., T1 to T2; and T2 to T3) were compared between groups (i.e., saline vs. IT-MTX + DEX). Results: Five mice in the IT-MTX + DEX group, and seven mice in the saline group completed all three scans. Between T1 and T2, volumetric change was significantly different between groups in total gray matter [estimate =2.06, 95% confidence interval (CI): 0.27–3.84], the cerebrum (estimate =1.62, 95% CI: 0.14–3.09), claustrum (estimate =0.06, 95% CI: 0.02–0.09), amygdala (estimate =0.16, 95% CI: 0.03–0.29), and striatum (estimate =0.18, 95% CI: 0.01–0.35), with the IT-MTX + DEX group exhibiting a more robust increase in volume than the saline-treated group. Between T2 and T3, group differences in structural brain development were evident for total white matter (estimate =−0.14, 95% CI: −0.27 to −0.01), and the corpus callosum (estimate =−0.09, 95% CI: −0.19 to 0.00) and amygdala (estimate =−0.05, 95% CI: −0.10 to 0.00). In contrast to the rapid brain growth observed earlier in development (i.e., T1 to T2), the IT-MTX + DEX group exhibited an attenuated increase in volume relative to the saline-treated group between T2 and T3. Conclusions: The results demonstrate feasibility of modeling pediatric ALL treatment in a preclinical model and highlight the potential of using preclinical neuroimaging models to gain insight into brain development throughout survivorship.
- Open Access
- 29 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (7) , 1267-1278
Subsequent kidney transplant after pediatric heart transplant: Prevalence and risk factors
- 29 February 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (7) , 1267-1278
Open AccessSubsequent kidney transplant after pediatric heart transplant: Prevalence and risk factors